These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 34687939)

  • 21. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
    Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
    Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [CAR T-cell bridging to allo-HSCT for relapsed/refractory B-cell acute lymphoblastic leukemia: the follow-up outcomes].
    Yan M; Wu YJ; Chen F; Tang XW; Han Y; Qiu HY; Sun AN; Xue SL; Jin ZM; Wang Y; Miao M; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):710-715. PubMed ID: 33113601
    [No Abstract]   [Full Text] [Related]  

  • 23. Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis.
    Xu X; Chen S; Zhao Z; Xiao X; Huang S; Huo Z; Li Y; Tu S
    Front Oncol; 2021; 11():651944. PubMed ID: 34026627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
    Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
    Jiang H; Hu Y; Mei H
    Biomark Res; 2020 Nov; 8(1):66. PubMed ID: 33292685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety of chimeric antigen receptor T-cell therapy followed by allogeneic hematopoietic stem cell transplantation in 21 patients with Ph-like acute lymphoblastic leukemia].
    Dai HP; Shen HJ; Li Z; Cui W; Cui QY; Li MY; Chen SF; Zhu MQ; Wu DP; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):35-40. PubMed ID: 38527836
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
    Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
    J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial.
    Wang T; Tang Y; Cai J; Wan X; Hu S; Lu X; Xie Z; Qiao X; Jiang H; Shao J; Yang F; Ren H; Cao Q; Qian J; Zhang J; An K; Wang J; Luo C; Liang H; Miao Y; Ma Y; Wang X; Ding L; Song L; He H; Shi W; Xiao P; Yang X; Yang J; Li W; Zhu Y; Wang N; Gu L; Chen Q; Tang J; Yang JJ; Cheng C; Leung W; Chen J; Lu J; Li B; Pui CH
    J Clin Oncol; 2023 Mar; 41(9):1670-1683. PubMed ID: 36346962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
    Zhang Y; Chen H; Song Y; Tan X; Zhao Y; Liu X; Li Z; Yang F; Jiang M; Gao Z; Wu T
    Br J Haematol; 2020 Apr; 189(1):146-152. PubMed ID: 31869864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tan X; Wang XQ; Zhang C; Zhao XL; Yao H; Chen G; Ma YY; Wen Q; Gao L; Gao L; Kong PY; Shen Y; Zhang X; Lou SF
    Curr Med Sci; 2023 Aug; 43(4):733-740. PubMed ID: 37330456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    Myers RM; Taraseviciute A; Steinberg SM; Lamble AJ; Sheppard J; Yates B; Kovach AE; Wood B; Borowitz MJ; Stetler-Stevenson M; Yuan CM; Pillai V; Foley T; Chung P; Chen L; Lee DW; Annesley C; DiNofia A; Grupp SA; John S; Bhojwani D; Brown PA; Laetsch TW; Gore L; Gardner RA; Rheingold SR; Pulsipher MA; Shah NN
    J Clin Oncol; 2022 Mar; 40(9):932-944. PubMed ID: 34767461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
    Gu J; Liu S; Cui W; Dai H; Cui Q; Yin J; Li Z; Kang L; Qiu H; Han Y; Miao M; Chen S; Xue S; Wang Y; Jin Z; Zhu X; Yu L; Wu D; Tang X
    Front Immunol; 2022; 13():858590. PubMed ID: 35371098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy.
    Yagi Y; Kanemasa Y; Sasaki Y; Goto S; Yamamura Y; Masuda Y; Fujita K; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Matsuda S; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Shimoyama T
    J Clin Exp Hematop; 2024; 64(2):107-118. PubMed ID: 38925972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia.
    McNerney KO; Moskop A; Winestone LE; Baggott C; Talano JA; Schiff D; Rossoff J; Modi A; Verneris MR; Laetsch TW; Schultz L
    Transplant Cell Ther; 2024 Jan; 30(1):75.e1-75.e11. PubMed ID: 37816472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.
    Lamble AJ; Myers RM; Taraseviciute A; John S; Yates B; Steinberg SM; Sheppard J; Kovach AE; Wood B; Borowitz MJ; Stetler-Stevenson M; Yuan CM; Pillai V; Foley T; Chung P; Chen L; Lee DW; Annesley C; DiNofia A; Grupp SA; Verneris MR; Gore L; Laetsch TW; Bhojwani D; Brown PA; Pulsipher MA; Rheingold SR; Gardner RA; Shah NN
    Blood Adv; 2023 Feb; 7(4):575-585. PubMed ID: 35482927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.